Review of fludarabine cellular pharmacology shows up to 14.5-fold exposure variability in hematological malignancy patients
Drug exposure varies wildly in patients receiving fludarabine for blood cancers
This review examines fludarabine cellular pharmacology, specifically transport and metabolism, in patients receiving the medication for hema…
Drug exposure varies up to 14.5-fold between patients receiving fludarabine, directly linking low levels to treatment failure and death.
Narrative review discusses adapter-based CAR T cells for solid tumors and hematological malignancies
Adapter-based CAR T cells face hurdles in treating solid tumors and blood cancers
This narrative review examines the potential of adapter-based CAR T cells across multiple cancer types, including solid tumors and hematolog…
A review highlights that making these cells is hard work and they struggle against solid tumors, limiting their current use.
Detection of TP53 variants distinguishes germline and somatic clonal expansions with associated cancer risk in UK Biobank participants
Hidden Blood Mutations Rewrite Cancer Risk Rules For Millions
This observational analysis of UK Biobank data examined TP53 variants to distinguish germline from somatic clonal expansions and assess asso…
Many scary cancer gene findings in blood tests are not inherited but acquired later in life, changing how doctors assess risk for millions.
Research across Hematologic Malignancies
Related studies from across the Hematologic Malignancies family.
B-cell depletion and S1P inhibitors significantly reduce mRNA vaccine binding antibody levels in immunocompromised patients
Immune treatments significantly lower antibody levels from mRNA vaccines
This meta-analysis evaluates mRNA vaccine binding antibody levels in patients receiving B-cell depletion, S1P inhibitors, or JAK inhibitors.…
Certain immune-suppressing medications significantly lower the amount of antibodies produced after mRNA vaccination, impacting protection le…
Busulfan-based conditioning favors survival in AML while TBI yields better outcomes in ALL
Busulfan Shows Survival Benefits for Patients with Acute Myeloid Leukemia
This meta-analysis of 26 studies compared Busulfan-based conditioning to total body irradiation for children and young adults undergoing hem…
Busulfan may offer better survival for certain leukemias while reducing long-term side effects like growth issues and cataracts in young pat…
Cryopreserved PBMC starting material is a feasible approach for CAR-T cell manufacturing in hematological malignancies
Cryopreserved Cells Show Potential for CAR-T Cell Manufacturing
This systematic review evaluates the impact of cryopreserved versus fresh PBMC starting materials on CAR-T cell manufacturing outcomes. The …
Frozen blood cells may work as a viable starting material for CAR-T cell therapy, showing similar expansion and activity to fresh cells.
Approximately 61% of cancer patients resume anticancer treatment after unplanned ICU admission
Most cancer patients do not resume treatment after ICU stay
This meta-analysis of 3551 patients with solid tumors or hematological malignancies found that 61% of patients resumed any anticancer treatm…
Only about 60% of cancer patients resume any treatment after an unplanned ICU stay, highlighting a critical gap in care after a medical cris…
Tocilizumab serves as first-line therapy for CRS in CAR-T and VST cellular immunotherapies
New guidelines offer clear paths for managing CAR-T cell complications
This clinical guideline provides a framework for managing early complications in patients receiving CAR-T cell or virus-specific T-lymphocyt…
New clinical guidelines provide clear steps for managing serious side effects like cytokine release syndrome in patients receiving CAR-T cel…
TET2 functions as a tumor suppressor in myeloid malignancies and immunomodulator in solid tumors
TET2 protein acts as a key regulator in several diseases
This systematic review examines the role of TET2 across various conditions including hematological malignancies, solid tumors, and inflammat…
A key protein called TET2 helps control cell behavior and may play a major role in treating cancer and inflammatory conditions.
Mitochondrial engineering enhances CAR-T cell therapy for solid and blood cancers
New cell therapy upgrade helps immune cells survive longer in tumors
A mini-review explores mitochondrial engineering strategies to boost CAR-T cell efficacy against solid and hematological malignancies, highl…
A new approach to engineering immune cells could solve a major problem: why they stop working inside solid tumors.
Systematic review of advancements and challenges in NK cell immunotherapy for malignancies
New NK cell therapies show promise for treating cancer
This systematic review evaluates Natural Killer (NK) cell immunotherapy, including CAR-NK, BiKEs, TriKEs, and CIML-NK cells, for hematologic…
New ways to use Natural Killer cells could help fight cancer while keeping the risk of dangerous immune reactions very low.
Systematic review of pharmacist-led interventions in hematological malignancies
Pharmacists Help Blood Cancer Patients Avoid Dangerous Drug Risks
This systematic review of 33 studies examined pharmacist-led interventions for patients with hematological malignancies.
Adding a pharmacist to your care team can make taking complex medicines safer.